Navigation Links
Medivation Announces Participation in Upcoming Conferences
Date:8/28/2008

SAN FRANCISCO, Aug. 28 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following conferences:

-- BioCentury's NewsMakers in the Biotech Industry on Thursday, September 4, at 9:00 a.m. Eastern Time at the Millennium Broadway Hotel & Conference Center

-- 2008 UBS Global Life Sciences Conference on Wednesday, September 24, at 4:30 p.m. Eastern Time at the Grand Hyatt New York

Dr. Hung will provide an overview of Medivation and its clinical development programs for Dimebon for Alzheimer's and Huntington's diseases and MDV3100 for prostate cancer.

A live audio webcast of each presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at http://www.medivation.com. A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial. For more information, please visit us at http://www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
2. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
3. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
4. Medivation Announces Senior Management Promotions
5. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
6. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
7. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
8. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
11. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... TORONTO , March 29, 2017 /PRNewswire/ -  GeneNews Limited ... of BreastSentry™ , a new risk stratification test for ... reference lab, Innovative Diagnostics Laboratory ("IDL"). BreastSentry incorporates a blood-based ... five-year and lifetime risk for developing breast cancer.   ... BreastSentry measures ...
(Date:3/28/2017)... Linda, Ca (PRWEB) , ... March 28, 2017 , ... ... various settings. The utilization of this technology is driven by its potential to perform ... tool, there are also some challenges that must be addressed for it to be ...
(Date:3/28/2017)... LONDON , March 28, 2017 ... to better understand Enzo Biochem and its partnering interests and ... since 2010 report provides an in-depth insight into the partnering ... On demand company reports are prepared upon purchase ... and company data. The report will be delivered ...
(Date:3/28/2017)... , March 28, 2017 Dr. ... life sciences corporation Anpac Bio-Medical Science Company ... new, international record, processing and reporting over 40,000 ... Differentiation Analysis" (CDA) liquid biopsy tests. ... Prize Laureate Summit publications, Anpac Bio,s CDA medical ...
Breaking Biology Technology:
(Date:2/28/2017)... , February 28, 2017 News solutions for ... ... from 14 to 16 March, Materna will present ... show how seamless travel is a real benefit for passengers. ... biometrics to their passenger touch point solutions to take passengers through ...
(Date:2/22/2017)... -- With the biometrics market to exceed $10 ... that innovative and agile startups must incorporate into ... changing competitive landscape: multifactor authentication (MFA), point-of-sale (PoS), ... "Companies can no longer afford to cut corners ... Pavlakis , Industry Analyst at ABI Research. "Pairing ...
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
Breaking Biology News(10 mins):